Edition:
India

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

117.70EUR
18 Sep 2020
Change (% chg)

€-1.45 (-1.22%)
Prev Close
€119.15
Open
€119.65
Day's High
€119.80
Day's Low
€117.10
Volume
475,793
Avg. Vol
475,290
52-wk High
€252.90
52-wk Low
€99.86

Select another date:

Wed, Jun 10 2020

BRIEF-E-Therapeutics Announces Collaboration With Galapagos

* E-THERAPEUTICS PLC - COLLABORATION WITH GALAPAGOS TO DISCOVER THERAPEUTIC STRATEGIES FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS Source text for Eikon: Further company coverage:

BRIEF-Galapagos: Capital Increase Of EUR 17.9 Million

* ANNOUNCED ON THURSDAY SHARE CAPITAL INCREASE THROUGH SUBSCRIPTION RIGHT EXERCISES

Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

Gilead Sciences Inc and partner Galapagos NV said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients.

UPDATE 2-Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

May 20 Gilead Sciences Inc and partner Galapagos NV said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients. Filgotinib is also in advanced stages of testing against multiple types of inflammatory conditions including rheumatoid arthritis, a market dominated by drugs such as AbbVie's Humira.

BRIEF-Gilead, Galapagos Announce Topline Results Of Phase 2b/3 Trial In Ulcerative Colitis

* GILEAD AND GALAPAGOS ANNOUNCE POSITIVE TOPLINE RESULTS OF PHASE 2B/3 TRIAL OF FILGOTINIB IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Gilead-Galapagos's drug meets main goals of ulcerative colitis study

May 20 Gilead Sciences Inc and partner Galapagos NV said on Wednesday a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a mid-stage study testing it in ulcerative colitis patients.

BRIEF-Galapagos Q1 Net Loss Widens To 50.6 Million Euros

* ANNOUNCED ON THURSDAY : FIRST THREE-MONTH 2020 FINANCIAL RESULTS

BRIEF-Galapagos Creates New Subscription Right Plans

* GALAPAGOS CREATES NEW SUBSCRIPTION RIGHT PLANS Source text for Eikon: Further company coverage:

BRIEF-Ryvu Therapeutics Signs R&D Cooperation Deal With Belgium-Based Galapagos

* SIGNS RESEARCH AND DEVELOPMENT COOPERATION DEAL WITH BELGIUM-BASED GALAPAGOS

BRIEF-Galapagos And Ryvu To Partner On Drug Discovery And Development

* TODAY ANNOUNCED A COLLABORATION FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL MOLECULE DRUGS IN INFLAMMATION

Select another date: